Image

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Investigation of Treatment Options for Residual Triple Negative Breast Cancer After Surgery

Recruiting
18 years and older
All
Phase 3
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates residual triple negative breast cancer. Participants have this condition remaining after surgery and neoadjuvant therapy, which is treatment given before surgery.

The study evaluates the safety and effectiveness of an investigational medication combined with another treatment, compared to the treatment chosen by doctors. It focuses on understanding how well these treatments work for patients with this type of breast cancer.

  • Who can participate: Adults over 18 years with residual invasive triple negative breast cancer after surgery and neoadjuvant therapy may qualify. Recovery from surgery and appropriate radiotherapy are required.
  • Study details: Participants will receive either the investigational medication with another treatment or the treatment chosen by their doctor. A placebo is not used in this study.
Print
Study details
    Triple Negative Breast Cancer

NCT05633654

Gilead Sciences

22 June 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.